Abstract:Fucosyl-N-acetylglucosamine disaccharides are present in many biologically important oligosaccharides, such as human milk oligosaccharides, Lewis carbohydrate antigens, and glycans on cell-surface glycoconjugate receptors, and thus have vast potential for infant formulas, prebiotics, and pharmaceutical applications. In this work, in order to screen biocatalysts for enzymatic synthesis of fucosyl-N-acetylglucosamine disaccharides, we performed sequence analysis of 12 putative and one known α-L-fucosidases of Bacteroides fragilis NCTC9343 and constructed a phylogenetic tree of the nine GH29 α-L-fucosidases. After that, five GH29A α-L-fucosidases were cloned, and four of them were successfully heterogeneous expressed and screened for transglycosylation activity, and a GH29A α-L-fucosidase (BF3242) that synthesized a mix of Fuc-α-1,3/1,6-GlcNAc disaccharides using pNPαFuc as donor and GlcNAc as acceptor was characterized. The effects of initial substrate concentration, pH, temperature, and reaction time on its transglycosylation activity were studied in detail. Under the optimum conditions of 0.05 U/mL enzyme, 20 mM pNPαFuc, and 500 mM GlcNAc in sodium buffer (pH 7.5) at 37 °C for 45 min, BF3242 efficiently synthesized Fuc-α-1,3/1,6-GlcNAc at a maximum yield of 79.0% with the ratio of 0.48 for 1,3/1,6. The molecular dynamics simulation analysis revealed that Loop-4 (His220-Ser245) in the putative 3D model of BF3242 displayed significant changes throughout the thermal simulations, might being responsible for the changes in the ratio of two regioisomeric products at different temperatures. This work provided not only a potential synthetic tool for enzymatic synthesis of fucosyl-N-acetylglucosamine disaccharides but also a possibility for the formation of regioisomeric products in glycosidase-catalyzed transglycosylation.Key points• Sequence analysis of α-L-fucosidases of Bacteroides fragilis NCTC9343• Obtainment of an α-L-fucosidase with high transglycosylation activity• Explanation why temperature affected the ratio of two regioisomeric products

Reprogramming the Enzymatic Assembly Line for Site-Specific Fucosylation

Chemoenzymatic Probes for Detecting and Imaging Fucose-Α(1-2)-galactose Glycan Biomarkers.

Redox-Controlled Site-Specific Alpha 2-6-Sialylation

A Redox‐Controlled Substrate Engineering Strategy for Site‐Specific Enzymatic Fucosylation

Exploring Regioselective Fucosylation Catalyzed by Bacterial Glycosyltransferases through Substrate Promiscuity and Acceptor-Mediated Glycosylation

One‐Pot Multienzyme Synthesis of Lewis x and Sialyl Lewis x Antigens

Enzymatic Modular Assembly of Hybrid Lewis Antigens

Targeted Fucosylation of Glycans with Engineered Bacterial Fucosyltransferase Variants

A Computational and Chemical Design Strategy for Manipulating Glycan‐Protein Recognition

Chemical Synthesis of Fucosylated Chondroitin Sulfate Tetrasaccharide with Fucosyl Branch at the 6-OH of GalNAc Residue

Chemoenzymatic Labeling, Detection and Profiling of Core Fucosylation in Live Cells

Screening and characterization of an α-L-fucosidase from Bacteroides fragilis NCTC9343 for synthesis of fucosyl-N-acetylglucosamine disaccharides

Chemical Synthesis of Fucosylated Chondroitin Sulfate Oligosaccharides

Appropriate aglycone modification significantly expands the glycan substrate acceptability of α1,6-fucosyltransferase (FUT8)

Enhancing lactose recognition of a key enzyme in 2'-fucosyllactose synthesis: α-1,2-fucosyltransferase

Chemical and chemoenzymatic syntheses of sialyl Lewisa tetrasaccharide antigen

Application of fucosylation inhibitors for production of afucosylated antibody

Synthesis of Asymmetric N -Glycans as Common Core Substrates for Structural Diversification through Selective Enzymatic Glycosylation

Enzyme-Sialylation-Controlled Chemical Sulfation of Glycan Epitopes for Decoding the Binding of Siglec Ligands

Sulfo-Fluorous Tagging Strategy for Site-Selective Enzymatic Glycosylation of para -Human Milk Oligosaccharides

Trimming Crystallizable Fragment (fc) Glycans Enables the Direct Enzymatic Transfer of Biomacromolecules to Antibodies As Therapeutics.